4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001415889-25-006494
Chief Financial Officer gave up 727 shares (to pay taxes)
- Chief Financial Officer acquired 3,475 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Balthaser Kevin Chief Financial Officer | 2025-03-01 | Option exercise | +1,100 | 90,960 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-03-01 | Option exercise | +2,375 | 93,335 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-03-01 | Shares withheld for taxes | −727 | $1.99 | $1,447 | 92,608 | D |
| Derivatives | |||||||
| Balthaser Kevin Chief Financial Officer | 2025-03-01 | Option exercise · Restricted Stock Units | −1,100 | 0 | D | ||
| Balthaser Kevin Chief Financial Officer | 2025-03-01 | Option exercise · Restricted Stock Units | −2,375 | 2,375 | D | ||
Loading xslF345X05/form4-03042025_040308.xml…